Trials / Completed
CompletedNCT01668069
Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy
Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- United States Naval Medical Center, San Diego · Federal
- Sex
- Female
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Our purpose is to determine whether ondansetron, a commonly used antiemetic, is equivalent in efficacy to the combination of pyridoxine and doxylamine, the currently recommended first line therapy for nausea and vomiting in pregnancy by the American Congress of Obstetricians and Gynecologists (ACOG). Since both treatments are safe in pregnancy, many physicians are using ondansetron as first line in practice. Despite this practice and the recommendations from ACOG, there is not data to suggest that ether practice is superior. This will be the first prospective, randomized, double blind, controlled trial comparing the two treatments. We hypothesize that ondansetron will be equally efficacious in reducing nausea and episodes of emesis. By alleviating nausea and vomiting associated with pregnancy, patients will likely benefit from less Emergency Department visits, urgent clinic visits, and admissions for progression to hyperemesis gravidarum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ondansetron | Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days. |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2012-10-01
- Completion
- 2013-04-01
- First posted
- 2012-08-17
- Last updated
- 2016-04-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01668069. Inclusion in this directory is not an endorsement.